Search results for "Sclerosis"

showing 3 items of 1583 documents

The Effects of Transcutaneous Spinal Direct Current Stimulation on Neuropathic Pain in Multiple Sclerosis: Clinical and Neurophysiological Assessment

2019

Background: Central neuropathic pain represents one of the most common symptoms in multiple sclerosis (MS) and it seriously affects quality of life. Spinal mechanisms may contribute to the pathogenesis of neuropathic pain in MS. Converging evidence from animal models and neurophysiological and clinical studies in humans suggests a potential effect of transcranial direct current stimulation (tc-DCS) on neuropathic pain. Spinal application of DCS, i.e., transcutaneous spinal DCS (ts-DCS), may modulate nociception through inhibition of spinal reflexes. Therefore, ts-DCS could represents an effective, safe and well-tolerated treatment for neuropathic pain in MS, a largely unexplored topic. This…

transcutaneous spinal direct current stimulation (ts-DCS)nociceptive withdrawal reflexmedicine.medical_treatmentnon-invasiveWithdrawal reflexmultiple sclerosis050105 experimental psychologylcsh:RC321-57103 medical and health sciencesBehavioral Neuroscience0302 clinical medicinemedicine0501 psychology and cognitive sciencesSpasticitylcsh:Neurosciences. Biological psychiatry. NeuropsychiatryBiological PsychiatryOriginal Researchneuropathic painTranscranial direct-current stimulationbusiness.industryMultiple sclerosis05 social sciencesmedicine.diseaseNeuromodulation (medicine)Psychiatry and Mental healthNeuropsychology and Physiological PsychologyNociceptionNeurologyAnesthesianeuromodulationNeuropathic painmultiple sclerosis; neuromodulation; neuropathic pain; nociceptive withdrawal reflex; non-invasive; transcutaneous spinal direct current stimulation (ts-DCS)Reflexmedicine.symptombusiness030217 neurology & neurosurgeryNeuroscienceFrontiers in Human Neuroscience
researchProduct

Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial

2022

Background and purpose: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options. RNS60 is an immunomodulatory and neuroprotective investigational product that has shown efficacy in animal models of ALS and other neurodegenerative diseases. Its administration has been safe and well tolerated in ALS subjects in previous early phase trials. Methods: This was a phase II, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial. Participants diagnosed with definite, probable or probable laboratory-supported ALS were assigned to receive RNS60 or placebo administered for 24 weeks intravenously (375 ml) once a week and via nebul…

treatmentAmyotrophic Lateral Sclerosisplacebo-controlledNeurodegenerative DiseasesALS; clinical trial; placebo-controlled; randomized; treatmentclinical trialTreatment OutcomeNeurologyDouble-Blind MethodrandomizedQuality of LifeHumansSettore MED/26 - NeurologiaNeurology (clinical)ALSBiomarkers
researchProduct

Prediction of vascular events in subjects with subclinical atherosclerosis and the metabolic syndrome: the role of markers of inflammation.

2010

vascular events atherosclerosis the metabolic syndrome inflammation
researchProduct